Reaction

Oral Intake Reduced reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,420 reports · 60 co-occurring drugs

As of the last recalculation, Oral Intake Reduced appears in 2,420 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 21.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gefitinib	22	21.1	21.2
Cisplatin	144	16.8	16.8
Calcium Gluconate	20	14.4	14.4
Leucovorin Calcium	30	13.7	13.7
Extended Phenytoin Sodium	25	13.0	13.0
Temozolomide	30	12.4	12.4
Warfarin Sodium	65	12.4	12.4
Glyburide	32	11.5	11.5
Dronabinol	10	10.7	10.7
Doxorubicin Hydrochloride	39	10.4	10.4
Cetuximab	37	10.3	10.3
Diphenoxylate Hydrochloride And Atropine Sulfate	16	10.1	10.1
Lithium Carbonate	19	9.7	9.7
Tolterodine Tartrate	10	9.6	9.6
Primidone	11	9.3	9.3
Lisinopril And Hydrochlorothiazide	11	9.3	9.3
Digoxin	73	9.0	9.0
Erlotinib	10	8.9	8.9
Fluorouracil Cream, 0.5%	76	8.8	8.8
Fluorouracil	76	8.7	8.7
Interferon Beta-1B	19	8.6	8.6
Irinotecan Hydrochloride	12	8.1	8.1
Lisinopril And Hydrochlorothiazide Tablets	7	7.7	7.7
Erlotinib Hydrochloride	11	7.6	7.6
Enalapril Maleate	21	7.3	7.3
Amlodipine Besylate And Benazepril Hydrochloride	7	6.5	6.5
Metformin Hcl	41	6.5	6.5
Olanzapine Pamoate	30	6.4	6.4
Lopinavir And Ritonavir	10	6.4	6.4
Gemfibrozil	11	6.3	6.3
Ribavirin	46	6.3	6.3
Lapatinib	11	6.1	6.1
Loperamide Hcl	9	6.0	6.0
Gemcitabine	27	6.0	6.0
Metoclopramide Hydrochloride	52	5.9	5.9
Warfarin	84	5.9	5.9
Phenytoin	14	5.8	5.8
Glipizide	40	5.7	5.7
Ziprasidone Mesylate	9	5.4	5.4
Eszopiclone	16	5.4	5.4
Sunitinib Malate	23	5.1	5.1
Capecitabine	53	5.1	5.1
Vincristine Sulfate	17	5.0	5.0
Exenatide	30	5.0	5.0
Ziprasidone	10	4.9	4.9
Donepezil Hydrochloride	20	4.7	4.7
Bevacizumab	66	4.7	4.7
Oxaliplatin	38	4.5	4.5
Carboplatin	64	4.4	4.4
Gemcitabine Hydrochloride	27	4.4	4.4
Levodopa	6	4.3	4.3
Thalidomide	18	4.2	4.2
Sorafenib	10	4.2	4.2
Imatinib Mesylate	13	4.0	4.0
Docetaxel Anhydrous	26	3.3	3.3
Docetaxel	26	3.3	3.3
Bortezomib	33	3.2	3.2
Varenicline Tartrate	24	2.6	2.6
Palivizumab	3	1.7	1.7
Pegfilgrastim	18	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.